103 related articles for article (PubMed ID: 16412524)
1. Molecular basis of Toxoplasma gondii atovaquone resistance modeled in Saccharomyces cerevisiae.
Kessl JJ; Ha KH; Merritt AK; Meshnick SR; Trumpower BL
Mol Biochem Parasitol; 2006 Apr; 146(2):255-8. PubMed ID: 16412524
[No Abstract] [Full Text] [Related]
2. Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate.
Pfefferkorn ER; Borotz SE; Nothnagel RF
J Parasitol; 1993 Aug; 79(4):559-64. PubMed ID: 8331476
[TBL] [Abstract][Full Text] [Related]
3. Multiple cytochrome B mutations may cause atovaquone resistance.
Meshnick SR; Trumpower B
J Infect Dis; 2005 Mar; 191(5):822; author reply 822-3. PubMed ID: 15688308
[No Abstract] [Full Text] [Related]
4. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance.
McFadden DC; Tomavo S; Berry EA; Boothroyd JC
Mol Biochem Parasitol; 2000 Apr; 108(1):1-12. PubMed ID: 10802314
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis.
Aspinall TV; Joynson DH; Guy E; Hyde JE; Sims PF
J Infect Dis; 2002 Jun; 185(11):1637-43. PubMed ID: 12023770
[TBL] [Abstract][Full Text] [Related]
7. Re-examination of inhibitor resistance conferred by Qo-site mutations in cytochrome b using yeast as a model system.
Fisher N; Meunier B
Pest Manag Sci; 2005 Oct; 61(10):973-8. PubMed ID: 15912560
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro activities of ferrocenic aminohydroxynaphthoquinones against Toxoplasma gondii and Plasmodium falciparum.
Baramee A; Coppin A; Mortuaire M; Pelinski L; Tomavo S; Brocard J
Bioorg Med Chem; 2006 Mar; 14(5):1294-302. PubMed ID: 16242338
[TBL] [Abstract][Full Text] [Related]
9. New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.
Ferreira RA; de Oliveira AB; Gualberto SA; Miguel Del Corral JM; Fujiwara RT; Gazzinelli Guimarães PH; de Almeida Vitor RW
Exp Parasitol; 2012 Dec; 132(4):450-7. PubMed ID: 23000485
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae.
Kessl JJ; Ha KH; Merritt AK; Lange BB; Hill P; Meunier B; Meshnick SR; Trumpower BL
J Biol Chem; 2005 Apr; 280(17):17142-8. PubMed ID: 15718226
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.
Huskinson-Mark J; Araujo FG; Remington JS
J Infect Dis; 1991 Jul; 164(1):170-1. PubMed ID: 1647421
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance.
Berry A; Senescau A; Lelièvre J; Benoit-Vical F; Fabre R; Marchou B; Magnaval JF
Trans R Soc Trop Med Hyg; 2006 Oct; 100(10):986-8. PubMed ID: 16690094
[TBL] [Abstract][Full Text] [Related]
13. Short report: cloning of the Babesia gibsoni cytochrome B gene and isolation of three single nucleotide polymorphisms from parasites present after atovaquone treatment.
Matsuu A; Miyamoto K; Ikadai H; Okano S; Higuchi S
Am J Trop Med Hyg; 2006 Apr; 74(4):593-7. PubMed ID: 16606990
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae.
Kessl JJ; Hill P; Lange BB; Meshnick SR; Meunier B; Trumpower BL
J Biol Chem; 2004 Jan; 279(4):2817-24. PubMed ID: 14576156
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome b mutation identified in a decoquinate-resistant mutant of Toxoplasma gondii.
McFadden DC; Boothroyd JC
J Eukaryot Microbiol; 1999; 46(5):81S-82S. PubMed ID: 10519259
[No Abstract] [Full Text] [Related]
16. Resistance as a tool in the study of old and new drug targets in Toxoplasma.
McFadden DC; Camps M; Boothroyd JC
Drug Resist Updat; 2001 Apr; 4(2):79-84. PubMed ID: 11512524
[TBL] [Abstract][Full Text] [Related]
17. Recapitulation in Saccharomyces cerevisiae of cytochrome b mutations conferring resistance to atovaquone in Pneumocystis jiroveci.
Hill P; Kessl J; Fisher N; Meshnick S; Trumpower BL; Meunier B
Antimicrob Agents Chemother; 2003 Sep; 47(9):2725-31. PubMed ID: 12936966
[TBL] [Abstract][Full Text] [Related]
18. The apicomplexan parasite Toxoplasma gondii generates pyridoxal phosphate de novo.
Knöckel J; Müller IB; Bergmann B; Walter RD; Wrenger C
Mol Biochem Parasitol; 2007 Mar; 152(1):108-11. PubMed ID: 17222923
[No Abstract] [Full Text] [Related]
19. Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
Ma C; Tran J; Gu F; Ochoa R; Li C; Sept D; Werbovetz K; Morrissette N
Antimicrob Agents Chemother; 2010 Apr; 54(4):1453-60. PubMed ID: 20145086
[TBL] [Abstract][Full Text] [Related]
20. Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment.
Musset L; Le Bras J; Clain J
Mol Biol Evol; 2007 Aug; 24(8):1582-5. PubMed ID: 17488741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
